Skip to main content

Compare Stocks

Date Range: 

 AlphatecPulmonxCardiovascular SystemsLuminexGenMark Diagnostics
SymbolNASDAQ:ATECNASDAQ:LUNGNASDAQ:CSIINASDAQ:LMNXNASDAQ:GNMK
Price Information
Current Price$15.08$39.86$37.66$36.59$24.04
52 Week RangeBuyBuyBuyHoldHold
MarketRank™
Overall Score1.01.41.61.51.5
Analysis Score1.54.32.51.02.0
Community Score2.02.12.62.03.1
Dividend Score0.00.00.00.80.0
Ownership Score0.80.02.51.71.7
Earnings & Valuation Score0.60.60.61.90.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldHold
Consensus Price Target$15.43$58.00$47.50$37.00$22.01
% Upside from Price Target2.31% upside45.51% upside26.13% upside1.12% upside-8.43% downside
Trade Information
Market Cap$1.45 billion$1.39 billion$1.49 billion$1.73 billion$1.76 billion
Beta1.53N/A1.190.613.02
Average Volume648,442322,462210,6031,033,5812,696,111
Sales & Book Value
Annual Revenue$113.43 million$32.60 million$236.54 million$334.64 million$88.02 million
Price / Sales12.9644.326.395.1719.96
CashflowN/AN/AN/A$0.58 per shareN/A
Price / CashN/AN/AN/A62.90N/A
Book Value$0.71 per shareN/A$7.62 per share$10.32 per share$0.21 per share
Price / Book21.244.943.55114.48
Profitability
Net Income$-57,000,000.00$-20,700,000.00$-27,240,000.00$-3,840,000.00$-47,350,000.00
EPS($1.09)N/A($0.79)($0.21)($0.82)
Trailing P/E RatioN/A0.00N/A93.82N/A
Forward P/E RatioN/AN/AN/A40.66N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-51.95%N/A-10.12%4.60%-16.95%
Return on Equity (ROE)-266.45%N/A-11.43%3.75%-39.36%
Return on Assets (ROA)-40.80%N/A-8.36%2.73%-13.02%
Dividend
Annual PayoutN/AN/AN/A$0.40N/A
Dividend YieldN/AN/AN/A1.09%N/A
Three-Year Dividend GrowthN/AN/AN/A54.17%N/A
Payout RatioN/AN/AN/AN/A N/A
Years of Consecutive Dividend GrowthN/AN/AN/A1 YearsN/A
Debt
Debt-to-Equity Ratio8.17%N/A0.08%0.39%0.75%
Current Ratio1.80%3.67%6.25%6.45%4.33%
Quick Ratio0.92%3.05%5.61%5.01%3.84%
Ownership Information
Institutional Ownership Percentage31.76%N/A89.70%88.09%96.94%
Insider Ownership Percentage28.18%N/A3.00%9.40%3.25%
Miscellaneous
Employees2962207791,325618
Shares Outstanding97.47 million36.25 million40.16 million47.31 million73.09 million
Next Earnings Date8/5/2021 (Estimated)8/3/2021 (Estimated)8/3/2021 (Estimated)8/3/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
GenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Recommendation of "Hold" by BrokeragesGenMark Diagnostics, Inc. (NASDAQ:GNMK) Given Average Recommendation of "Hold" by Brokerages
americanbankingnews.com - May 4 at 10:52 AM
GenMark Diagnostics, Inc. (NASDAQ:GNMK) Short Interest Down 37.1% in AprilGenMark Diagnostics, Inc. (NASDAQ:GNMK) Short Interest Down 37.1% in April
americanbankingnews.com - April 30 at 8:54 AM
GenMark Investor Wants Records On $1.8B Roche DealGenMark Investor Wants Records On $1.8B Roche Deal
law360.com - April 21 at 11:59 PM
why GenMark Diagnostics Inc. [GNMK] is a Good Choice for Investors After New Price Target of $23.03why GenMark Diagnostics Inc. [GNMK] is a Good Choice for Investors After New Price Target of $23.03
dbtnews.com - April 16 at 10:02 PM
SHAREHOLDER ALERT: WeissLaw LLP Reminds GNMK, LDKB, PBCT, and CTB Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: WeissLaw LLP Reminds GNMK, LDKB, PBCT, and CTB Shareholders About Its Ongoing Investigations
finance.yahoo.com - April 12 at 7:53 PM
Shares in Italys DiaSorin jump after $1.8 bln Luminex acquisitionShares in Italy's DiaSorin jump after $1.8 bln Luminex acquisition
nasdaq.com - April 12 at 9:26 AM
The Trend in GenMark Diagnostics, Inc. (NASDAQ:GNMK) Continues to Point DownwardsThe Trend in GenMark Diagnostics, Inc. (NASDAQ:GNMK) Continues to Point Downwards
stocksregister.com - March 29 at 5:30 PM
GenMark Diagnostics Inc. [GNMK] moved up 1.00: Why It’s ImportantGenMark Diagnostics Inc. [GNMK] moved up 1.00: Why It’s Important
dbtnews.com - March 26 at 6:47 PM
Roche Begins Tender Offer For GenMark Diagnostics For $24.05/shr In CashRoche Begins Tender Offer For GenMark Diagnostics For $24.05/shr In Cash
markets.businessinsider.com - March 25 at 10:44 PM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPCO, STAY, GNMK, WIFI; Shareholders Are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates TPCO, STAY, GNMK, WIFI; Shareholders Are Encouraged to Contact the Firm
finance.yahoo.com - March 25 at 2:33 AM
Why Roches $1.8 Billion Acquisition of GenMark Is a Smart MoveWhy Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
finance.yahoo.com - March 24 at 6:30 AM
Why Roches $1.8 Billion Acquisition of GenMark Is a Smart MoveWhy Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
finance.yahoo.com - March 24 at 6:30 AM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, STAY, GNMK, NTEC, RNET; Shareholders are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, STAY, GNMK, NTEC, RNET; Shareholders are Encouraged to Contact the Firm
finance.yahoo.com - March 23 at 2:44 PM
GenMark Diagnostics (GNMK) Enters Overbought TerritoryGenMark Diagnostics (GNMK) Enters Overbought Territory
finance.yahoo.com - March 23 at 9:43 AM
BREAKING NEWS ALERT: Halper Sadeh LLP Continues to Investigate PRAH, RMBL, GNMK, FLIR; Shareholders Are Encouraged to Contact the FirmBREAKING NEWS ALERT: Halper Sadeh LLP Continues to Investigate PRAH, RMBL, GNMK, FLIR; Shareholders Are Encouraged to Contact the Firm
finance.yahoo.com - March 20 at 1:37 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMKSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK
markets.businessinsider.com - March 19 at 11:19 PM
GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMKGENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK
finance.yahoo.com - March 17 at 6:39 PM
3 Cancer Diagnostic Stocks To Watch Following Roches GenMark Buy3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
markets.businessinsider.com - March 16 at 2:36 PM
Moore Kuehn Encourages SLGG, GNMK, STAY, and NBLX Investors to Contact Law FirmMoore Kuehn Encourages SLGG, GNMK, STAY, and NBLX Investors to Contact Law Firm
finance.yahoo.com - March 16 at 2:36 PM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates STAY, GNMK, RMBL, FI, NTEC; Shareholders are Encouraged to Contact the FirmINVESTIGATION ALERT: Halper Sadeh LLP Investigates STAY, GNMK, RMBL, FI, NTEC; Shareholders are Encouraged to Contact the Firm
finance.yahoo.com - March 16 at 2:36 PM
GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is ...GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is ...
apnews.com - March 16 at 9:34 AM
GNMK Grabs Fresh Highs on Billion-Dollar Buyout BuzzGNMK Grabs Fresh Highs on Billion-Dollar Buyout Buzz
finance.yahoo.com - March 15 at 7:19 PM
GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...
businesswire.com - March 15 at 7:19 PM
GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd.GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd.
finance.yahoo.com - March 15 at 7:19 PM
SHAREHOLDER ALERT: WeissLaw LLP Investigates GenMark Diagnostics, Inc.SHAREHOLDER ALERT: WeissLaw LLP Investigates GenMark Diagnostics, Inc.
finance.yahoo.com - March 15 at 7:19 PM
DateCompanyBrokerageAction
4/9/2021AlphatecCanaccord GenuityReiterated Rating
3/11/2021AlphatecHC WainwrightBoost Price Target
3/5/2021AlphatecPiper SandlerBoost Price Target
12/18/2020AlphatecLake Street CapitalBoost Price Target
10/19/2020AlphatecStifel NicolausInitiated Coverage
9/3/2020AlphatecCowenInitiated Coverage
6/18/2020AlphatecNorthland SecuritiesInitiated Coverage
10/31/2019AlphatecPiper Jaffray CompaniesBoost Price Target
4/1/2021PulmonxCitigroupInitiated Coverage
4/1/2021PulmonxCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/16/2021PulmonxBank of AmericaUpgrade
3/9/2021PulmonxMorgan StanleyBoost Price Target
3/3/2021PulmonxWells Fargo & CompanyBoost Price Target
3/17/2021Cardiovascular SystemsOppenheimerReiterated Rating
2/15/2021Cardiovascular SystemsAegisReiterated Rating
2/4/2021Cardiovascular SystemsNeedham & Company LLCBoost Price Target
12/14/2020Cardiovascular SystemsSVB LeerinkBoost Price Target
7/17/2020Cardiovascular SystemsBarclaysInitiated Coverage
10/17/2019Cardiovascular SystemsGuggenheimInitiated Coverage
4/19/2021LuminexBTIG ResearchReiterated Rating
4/12/2021LuminexJPMorgan Chase & Co.Upgrade
5/7/2019LuminexWilliam BlairReiterated Rating
8/7/2018LuminexJefferies Financial GroupReiterated Rating
2/11/2020GenMark DiagnosticsRaymond JamesDowngrade
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.